OBJECTIVE: We evaluated roles of serotonin 1B and 2A receptors, thromboxane synthase and receptor, and phospholipases A(2) and C in response to cardiopulmonary bypass. METHODS: Patients' atrial tissues were harvested before and after cardiopulmonary bypass with cardioplegia (n = 13). Coronary microvessels were assessed for vasoactive response to serotonin with and without inhibitors of serotonin 1B and 2A receptors and phospholipases A(2) and C. Expressions of serotonin receptor messenger RNA were determined with reverse transcriptase polymerase chain reaction. Expressions of serotonin receptors and thromboxane A(2) receptor and synthase proteins were determined with immunoblotting and immunohistochemistry. RESULTS: Microvessel exposure to serotonin elicited 7.3% +/- 2% relaxation before bypass, changing to contraction of -19.2% +/- 2% after bypass (P <.001). Additions of specific serotonin 1B receptor antagonist and inhibitor of phospholipase A(2) resulted in significantly decreased contraction, -8.6% +/- 1% (P < .001) and 2.8% +/- 3% (P = .001), respectively. Serotonin 1B receptor messenger RNA expression increased 1.82 +/- 0.34-fold after bypass (p = .044); serotonin 2A receptor messenger RNA expression did not change. Serotonin 1B but not 2A receptor protein expression increased after bypass by 1.35 +/- 0.7-fold (P = .0413). Thromboxane synthase and receptor expressions were unchanged after bypass. Serotonin 1B receptor increased mainly in arterial smooth muscle. There were no appreciable differences in arterial expressions of thromboxane synthase or receptor. CONCLUSIONS: Serotonin-induced vascular dysfunction after cardiopulmonary bypass with cardioplegic arrest may be mediated by increased expression of serotonin 1B receptor and subsequent phospholipase A(2) activation in myocardial coronary smooth muscle. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVE: We evaluated roles of serotonin 1B and 2A receptors, thromboxane synthase and receptor, and phospholipases A(2) and C in response to cardiopulmonary bypass. METHODS:Patients' atrial tissues were harvested before and after cardiopulmonary bypass with cardioplegia (n = 13). Coronary microvessels were assessed for vasoactive response to serotonin with and without inhibitors of serotonin 1B and 2A receptors and phospholipases A(2) and C. Expressions of serotonin receptor messenger RNA were determined with reverse transcriptase polymerase chain reaction. Expressions of serotonin receptors and thromboxane A(2) receptor and synthase proteins were determined with immunoblotting and immunohistochemistry. RESULTS: Microvessel exposure to serotonin elicited 7.3% +/- 2% relaxation before bypass, changing to contraction of -19.2% +/- 2% after bypass (P <.001). Additions of specific serotonin 1B receptor antagonist and inhibitor of phospholipase A(2) resulted in significantly decreased contraction, -8.6% +/- 1% (P < .001) and 2.8% +/- 3% (P = .001), respectively. Serotonin 1B receptor messenger RNA expression increased 1.82 +/- 0.34-fold after bypass (p = .044); serotonin 2A receptor messenger RNA expression did not change. Serotonin 1B but not 2A receptor protein expression increased after bypass by 1.35 +/- 0.7-fold (P = .0413). Thromboxane synthase and receptor expressions were unchanged after bypass. Serotonin 1B receptor increased mainly in arterial smooth muscle. There were no appreciable differences in arterial expressions of thromboxane synthase or receptor. CONCLUSIONS:Serotonin-induced vascular dysfunction after cardiopulmonary bypass with cardioplegic arrest may be mediated by increased expression of serotonin 1B receptor and subsequent phospholipase A(2) activation in myocardial coronary smooth muscle. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: Jie Xu; Bo Jian; Richard Chu; Zhibin Lu; Quanyi Li; John Dunlop; Sharon Rosenzweig-Lipson; Paul McGonigle; Robert J Levy; Bruce Liang Journal: Am J Pathol Date: 2002-12 Impact factor: 4.307
Authors: B Rondelet; R Van Beneden; F Kerbaul; S Motte; P Fesler; K McEntee; S Brimioulle; J M Ketelslegers; R Naeije Journal: Eur Respir J Date: 2003-09 Impact factor: 16.671
Authors: T Ishida; S Kawashima; T Sakoda; Y Shimokawa; Y Miwa; N Inoue; T Ueyama; M Shiomi; H Akita; M Yokoyama Journal: Circulation Date: 2001-03-06 Impact factor: 29.690
Authors: Michael P Robich; Robert M Osipov; Louis M Chu; Jun Feng; Thomas A Burgess; Shizu Oyamada; Richard T Clements; Roger J Laham; Frank W Sellke Journal: J Am Coll Surg Date: 2010-08-21 Impact factor: 6.113
Authors: Michael P Robich; Louis M Chu; Thomas A Burgess; Jun Feng; Cesario Bianchi; Frank W Sellke Journal: J Cardiovasc Pharmacol Date: 2011-01 Impact factor: 3.105
Authors: Jun Feng; Yuhong Liu; Arun K Singh; Nikola Dobrilovic; William C Feng; Louis M Chu; Michael P Robich; Kamal R Khabbaz; Frank W Sellke Journal: Surgery Date: 2011-08 Impact factor: 3.982
Authors: Nicholas Sellke; Alex Kuczmarski; Isabella Lawandy; Victoria L Cole; Afshin Ehsan; Arun K Singh; Yuhong Liu; Frank W Sellke; Jun Feng Journal: J Thorac Cardiovasc Surg Date: 2018-06-08 Impact factor: 5.209
Authors: Michael P Robich; Robina Matyal; Louis M Chu; Jun Feng; Shu-Hua Xu; Roger J Laham; Philip E Hess; Cesario Bianchi; Frank W Sellke Journal: J Mol Cell Cardiol Date: 2010-09-06 Impact factor: 5.000
Authors: Victor Lamin; Amenah Jaghoori; Rachel Jakobczak; Irene Stafford; Tamila Heresztyn; Michael Worthington; James Edwards; Fabiano Viana; Robert Stuklis; David P Wilson; John F Beltrame Journal: J Am Heart Assoc Date: 2018-07-09 Impact factor: 5.501